Fen-Phen were diet drugs whereby combining fenfluramine and phentermine was promoted by their manufacturers American Home Products (AHP), now Wyeth, Pondimin was the brand name for fenfluramine. Redux (dexfenfluramine), a diet drug chemically similar to Pondimin was single pill into which the two were combined . Enormous profits were made from these drugs despite the fact that their combined use was neither approved by the FDA nor tested by the drug companies marketing them for long-term safety and effectiveness. In September 1997, Pondimin and Redux were withdrawn from the market after the FDA learned of reports of hundreds of cases of Primary Pulmonary Hypertension (PPH), a deadly disease, and many reports of heart valve disorders in patients who took Pondimin (Fen-Phen) or Redux.
In addition to representing many individual fen-Phen users, Williams Cuker Berezofsky was also of the lead trial firms in the New Jersey Medical Monitoring Class Action trial. In this class action we represented thousands of New Jersey residents who had taken fen-Phen, exposing them to an increased risk of cardiovascular disease in order so that they could avail themselves of testing to determine if they had suffered heart damage. represented individuals with Primary Pulmonary Hypertension (PPH) and heart valve damage who took Fen-Phen. The trial ultimately lead to a national settlement and a medical surveillance program established.
To consult with a member of the firm's Diet Drug practice group, please submit a confidential case inquiry form.